| 指标 | 蓝帆医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 58.62亿元 | 116.69亿元 | 62 124 | | 净资产 | 97.07亿元 | 38.93亿元 | 7 124 | | 净利润 | -2.86亿元 | 2.12亿元 | 124 124 | | 市盈率(动) | -15.37 | 60.71 | - 124 | | 市净率 | 0.76 | 4.08 | 1 124 | | 毛利率 | 13.66% | 51.22% | 121 124 | | 净利率 | -7.24% | 9.57% | 109 124 | | ROE | -3.56% | 0.15% | 117 124 | 证券之星消息，截至2025年11月12日收盘，蓝帆医疗(002382)报收于5.82元，上涨0.87%，换手率 1.39%，成交量13.9万手，成交额8100.58万元。 11月12日的资金流向数据方面，主力资金净流出410.47万元，占总成交额5.07%，游资资金净流入 123.13万元，占总成交额1.52%，散户资金净流入287.34万 ...

Core Viewpoint - Bluefan Medical (002382) has shown a slight increase in stock price but continues to face significant financial challenges, with declining revenues and profits in recent quarters [1][3]. Financial Performance - As of November 3, 2025, Bluefan Medical's stock closed at 5.51 yuan, up 0.18% with a trading volume of 74,000 shares and a turnover of 40.68 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 14.01 billion yuan, a year-on-year decrease of 15.02%, and a net profit attributable to shareholders of -1.51 billion yuan, a decline of 153.64% [3]. - For the first three quarters of 2025, the total revenue was 41.82 billion yuan, down 10.15%, with a net profit of -2.86 billion yuan, a decrease of 30.09% [3]. Market Position - Bluefan Medical's total market capitalization is 5.549 billion yuan, ranking 64th in the medical device industry, which has an average market cap of 11.617 billion yuan [3]. - The company's net asset value stands at 9.707 billion yuan, significantly higher than the industry average of 3.893 billion yuan, ranking 7th [3]. - The company has a price-to-earnings ratio of -14.55, while the industry average is 63.42, indicating a challenging profitability outlook [3]. Profitability Metrics - Bluefan Medical's gross margin is 13.66%, compared to the industry average of 51.22%, ranking 121st in the industry [3]. - The net profit margin is -7.24%, significantly lower than the industry average of 9.57%, ranking 109th [3]. - The return on equity (ROE) is -3.56%, while the industry average is 0.15%, indicating poor financial performance relative to peers [3]. Capital Flow Analysis - On November 3, 2025, the net outflow of main funds was 2.3752 million yuan, accounting for 5.84% of the total turnover, while retail investors saw a net inflow of 1.4859 million yuan, representing 3.65% of the total turnover [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from main funds on several days, indicating a lack of confidence from institutional investors [2].

Core Insights - Bluefan Medical (002382) reported a closing price of 5.62 yuan on October 27, 2025, with a decrease of 0.35% and a trading volume of 76,700 hands, resulting in a transaction amount of 43.11 million yuan [1] Fund Flow Analysis - On October 27, 2025, the net outflow of main funds was 6.6866 million yuan, accounting for 15.51% of the total transaction amount, while retail investors saw a net inflow of 3.5591 million yuan, representing 8.26% of the total transaction amount [1][2] - Over the past five days, the main funds experienced consistent outflows, with the largest outflow recorded on October 22 at 2.8389 million yuan, while retail investors consistently showed net inflows [2] Company Performance Metrics - Bluefan Medical's total market value is 5.66 billion yuan, significantly lower than the industry average of 11.652 billion yuan, ranking 62 out of 124 in the medical device industry [3] - The company reported a net profit of -135 million yuan, with a year-on-year decline in main revenue of 7.49% to 2.781 billion yuan [3] - The gross profit margin stands at 14.34%, which is considerably lower than the industry average of 51.35%, ranking 120 out of 124 [3] - The company's debt ratio is 41.19%, with financial expenses amounting to 69.4351 million yuan [3]

该股主要指标及行业内排名如下： 证券之星消息，截至2025年10月20日收盘，蓝帆医疗(002382)报收于5.68元，上涨3.27%，换手率 1.57%，成交量15.65万手，成交额8886.36万元。 10月20日的资金流向数据方面，主力资金净流入977.42万元，占总成交额11.0%，游资资金净流入519.7 万元，占总成交额5.85%，散户资金净流出1497.12万元，占总成交额16.85%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-20 | 5.68 3.27% | | 977.42万 | 11.00% | 519.70万 | 5.85% | -1497.12万 | -16.85% | | 2025-10-17 | 5.50 -1.43% | | -477.88万 | -11.61% | 100.75万 | 2.45% | 377.13万 | 9.17% | | ...

证券之星消息，截至2025年10月14日收盘，蓝帆医疗(002382)报收于5.6元，上涨1.45%，换手率 0.93%，成交量9.28万手，成交额5179.09万元。 10月14日的资金流向数据方面，主力资金净流入278.5万元，占总成交额5.38%，游资资金净流出205.53 万元，占总成交额3.97%，散户资金净流出72.97万元，占总成交额1.41%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-14 | 5.60 | 1.45% | 278.50万 | 5.38% | -205.53万 | -3.97% | -72.97万 | -1.41% | | 2025-10-13 | | 5.52 -1.60% | -791.06万 | -15.15% | 380.38万 | 7.29% | 410.68万 | 7.87% | | 2025-10-10 | | 5.61 0. ...

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, with significant net outflows from major funds, indicating potential challenges in the market [1][2]. Financial Performance - As of the latest report, Bluefan Medical's total revenue for the first half of 2025 was 2.781 billion yuan, a year-on-year decrease of 7.49% [2]. - The company reported a net profit of -135 million yuan, which is an increase of 15.88% year-on-year, indicating worsening profitability despite the increase in losses [2]. - The second quarter of 2025 saw a single-quarter revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a significant decline of 245.53% year-on-year [2]. Market Position - Bluefan Medical's total market capitalization is 5.64 billion yuan, significantly lower than the industry average of 12.177 billion yuan, ranking 63rd out of 123 companies in the medical device sector [2]. - The company's net assets stand at 9.905 billion yuan, which is above the industry average of 3.889 billion yuan, ranking 7th in the industry [2]. - The price-to-earnings ratio (P/E) is -20.92, compared to the industry average of 67.16, indicating a lack of profitability [2]. Profitability Metrics - Bluefan Medical's gross margin is 14.34%, significantly lower than the industry average of 51.85%, ranking 120th in the industry [2]. - The net profit margin is -5.14%, compared to the industry average of 10.39%, ranking 106th [2]. - Return on equity (ROE) is -1.66%, while the industry average is 1.8%, ranking 112th [2]. Fund Flow Analysis - On October 9, 2025, Bluefan Medical's stock closed at 5.6 yuan, down 0.18%, with a turnover rate of 0.79% and a trading volume of 79,200 hands, amounting to a total transaction value of 44.1552 million yuan [1]. - The net outflow of major funds on the same day was 8.566 million yuan, accounting for 19.4% of the total transaction value, while retail investors saw a net inflow of 4.7937 million yuan, representing 10.86% of the total [1].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][2]. Financial Performance - As of September 22, 2025, Bluefan Medical's stock closed at 5.7 yuan, down 1.04%, with a trading volume of 67,900 hands and a transaction amount of 38.77 million yuan [1]. - The company's total revenue for the first half of 2025 was 2.781 billion yuan, a year-on-year decrease of 7.49% [2]. - The net profit attributable to shareholders was -135 million yuan, a year-on-year increase of 15.88% [2]. - The second quarter of 2025 saw a single-quarter revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a decrease of 245.53% year-on-year [2]. Market Position - Bluefan Medical's total market capitalization is 5.741 billion yuan, significantly lower than the industry average of 11.909 billion yuan, ranking 61 out of 123 in the medical device sector [2]. - The company has a net asset value of 9.905 billion yuan, which is higher than the industry average of 3.889 billion yuan, ranking 7 out of 123 [2]. - The company's price-to-earnings ratio is -21.3, while the industry average is 64.67, indicating a challenging profitability outlook [2]. Profitability Metrics - Bluefan Medical's gross margin is 14.34%, significantly lower than the industry average of 51.85%, ranking 120 out of 123 [2]. - The net profit margin stands at -5.14%, compared to the industry average of 10.39%, ranking 106 out of 123 [2]. - The return on equity (ROE) is -1.66%, while the industry average is 1.8%, ranking 112 out of 123 [2]. Capital Flow - On September 22, 2025, the net outflow of main funds was 5.551 million yuan, accounting for 14.32% of the total transaction amount [1]. - Retail investors showed a net inflow of 5.8796 million yuan, representing 15.16% of the total transaction amount on the same day [1].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of September 15, 2025, Bluefan Medical's stock closed at 5.83 yuan, down 1.19% with a trading volume of 10.4 million shares and a turnover of 60.62 million yuan [1]. - The company's main revenue for the first half of 2025 was 2.781 billion yuan, a year-on-year decrease of 7.49% [3]. - The net profit attributable to shareholders was -135 million yuan, a year-on-year increase of 15.88% [3]. - The second quarter of 2025 saw a single-quarter main revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, down 245.53% year-on-year [3]. Market Position - Bluefan Medical's total market value is 5.872 billion yuan, significantly lower than the industry average of 12.186 billion yuan, ranking 62 out of 123 in the medical device sector [3]. - The company's net assets stand at 9.905 billion yuan, ranking 7 out of 123 in the industry [3]. - The price-to-earnings ratio is -21.78, while the industry average is 69.25, indicating a challenging valuation environment [3]. Profitability Metrics - Bluefan Medical's gross margin is 14.34%, compared to the industry average of 51.85%, ranking 120 out of 123 [3]. - The net profit margin is -5.14%, significantly lower than the industry average of 10.39%, ranking 106 out of 123 [3]. - Return on equity (ROE) is -1.66%, ranking 112 out of 123 in the industry [3]. Capital Flow - On September 15, 2025, the net outflow of main funds was 1.6835 million yuan, accounting for 2.78% of the total turnover [1][2]. - Retail investors showed a net inflow of 5.5488 million yuan, representing 9.15% of the total turnover [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant outflows from main and speculative funds on various days [2].

Core Viewpoint - Bluefan Medical (002382) shows a mixed performance in stock price and fund flow, with a slight increase in stock price but significant net outflows from major funds [1][2]. Fund Flow Summary - On August 25, 2025, Bluefan Medical's stock closed at 6.52 CNY, up 1.4%, with a turnover rate of 3.14% and a trading volume of 314,300 hands, resulting in a transaction amount of 204 million CNY [1]. - The fund flow data indicates a net outflow of 10.38 million CNY from major funds, accounting for 5.09% of the total transaction amount, while retail funds saw a net inflow of 14.35 million CNY, representing 7.04% of the total [1][2]. - Over the past five days, the stock experienced fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2]. Company Performance Metrics - As of the latest report, Bluefan Medical has a total market value of 6.566 billion CNY, with a net asset value of 10.102 billion CNY, and a net profit of 77.0223 million CNY [3]. - The company’s price-to-earnings ratio (P/E) stands at 21.31, significantly lower than the industry average of 75.1, while the price-to-book ratio (P/B) is 0.81, compared to the industry average of 4.05 [3]. - The gross margin is reported at 17.17%, which is considerably lower than the industry average of 51.32%, and the net profit margin is 5.58%, below the industry average of 10.74% [3]. - In the first quarter of 2025, Bluefan Medical reported a main business revenue of 1.478 billion CNY, a year-on-year increase of 1.59%, and a net profit attributable to shareholders of 77.0223 million CNY, a significant year-on-year increase of 177.86% [3].

Core Viewpoint - As of August 22, 2025, BluFan Medical (002382) closed at 6.43 yuan, down 0.92%, with a trading volume of 289,400 hands and a transaction amount of 186 million yuan [1] Group 1: Stock Performance and Trading Data - On August 22, 2025, the net inflow of main funds was 809,000 yuan, accounting for 0.44% of the total transaction amount, while retail investors had a net outflow of 6.5073 million yuan, accounting for 3.5% of the total transaction amount [1] - Over the past five days, the stock has experienced fluctuations in trading volume and price, with notable changes in net inflows and outflows from different investor categories [1] Group 2: Company Financial Metrics and Industry Comparison - BluFan Medical's total market value is 6.476 billion yuan, with a net asset of 10.102 billion yuan, and a net profit of 77.0223 million yuan, ranking 57th, 7th, and 32nd respectively in the medical device industry [2] - The company reported a revenue of 1.478 billion yuan for Q1 2025, a year-on-year increase of 1.59%, while the net profit increased by 177.86% [2] - The company's financial ratios include a price-to-earnings ratio of 21.02, a price-to-book ratio of 0.8, and a gross margin of 17.17%, which are significantly lower than the industry averages [2]